Medication guides

Medicines used in rheumatology

How each medicine works, how it’s taken, common side effects and the monitoring that keeps treatment safe. Brand names are listed for reference.

Biologics

20 guides

Abatacept

Orencia

A biologic that stops T cells from fully switching on, calming the inflammatory chain at an early step.

Adalimumab

Humira and biosimilars (Amjevita, Cyltezo, Hadlima, Hyrimoz, Yuflyma, Simlandi, Idacio and others)

A TNF inhibitor biologic that blocks one of the main drivers of inflammation in arthritis.

Anakinra

Kineret

A short-acting IL-1 blocker used for autoinflammatory diseases and difficult gout.

Anifrolumab

Saphnelo

A biologic for lupus that blocks the type I interferon receptor.

Belimumab

Benlysta

The first biologic approved for lupus, which reduces the survival signals B cells depend on.

Bimekizumab

Bimzelx

A biologic that blocks both IL-17A and IL-17F.

Canakinumab

Ilaris

A long-acting IL-1 inhibitor.

Certolizumab

Cimzia

A TNF inhibitor with a structure that crosses the placenta very little.

Etanercept

Enbrel and biosimilars (Erelzi, Eticovo)

A TNF-blocking biologic used for inflammatory arthritis and psoriasis.

Golimumab

Simponi (injection), Simponi Aria (infusion)

A TNF inhibitor available as a monthly injection or an infusion every 8 weeks.

Guselkumab

Tremfya

An IL-23 inhibitor for psoriatic arthritis, psoriasis and bowel disease.

Infliximab

Remicade and biosimilars (Inflectra, Renflexis, Avsola), Zymfentra (under the skin)

An intravenous TNF inhibitor used for arthritis and inflammatory bowel disease.

Ixekizumab

Taltz

An IL-17A inhibitor with strong effects on skin and joints.

Mepolizumab

Nucala

An IL-5 blocker that lowers eosinophils, used for EGPA and severe asthma.

Risankizumab

Skyrizi

An IL-23 inhibitor given every 12 weeks.

Rituximab

Rituxan and biosimilars (Truxima, Ruxience, Riabni)

A biologic that removes B cells, the immune cells that make antibodies.

Sarilumab

Kevzara

An IL-6 receptor blocker given as an injection every two weeks.

Secukinumab

Cosentyx

An IL-17 inhibitor for psoriatic disease and spondyloarthritis.

Tocilizumab

Actemra and biosimilars (Tofidence, Tyenne)

A biologic that blocks the IL-6 receptor, a major inflammation pathway.

Ustekinumab

Stelara and biosimilars (Wezlana, Selarsdi, Pyzchiva, Otulfi and others)

A biologic that blocks IL-12 and IL-23, used in psoriatic disease and bowel disease.

Educational information only. Your own care plan should come from your physician, who knows your full history.